IXENSOR
27.7.2021 08:32:07 CEST | Business Wire | Press release
iXensor Co., Ltd. (6734.TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005852/en/
iXensor launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal . The PixoHealth Pass Admin App is a virtual gatekeeper, which screens and verifies the COVID-19 related health conditions through a scan of QR code displayed by PixoHealth Pass App users. In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest® POCT Analyzer simultaneously.
With PixoHealth Pass apps and in-app consent, the authorized institution can track app users’ rapid test results, vaccination status and COVID-19 related symptoms directly on the web portal. The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup. In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
The cloud-based data management solution helps streamline COVID-19 testing and point-of-entry screening for semi-closed communities, such as schools, corporations, healthcare facilities, and public health organizations. More important, the computer-vision enabled PixoTest POCT Analyzer detects COVID-19 antigens more accurately than most COVID-19 self-tests. In addition, its wireless connectivity enables easy, fast reporting and case management for routine testing and mass screening, making the reopen of social and economic activities safer and more sustainable.
The PixoTest® POCT COVID-19 Antigen Test detects the nucleoproteins of SARS-CoV-2 in the human nasopharynx and anterior nasal cavity. According to recent technical validation, the PixoTest® POCT COVID-19 Antigen Test proved its ability to capture recombinant nucleocapsid proteins of notable variants, including Alpha, Beta, Gamma and Delta. These variants have undergone mutations in spike proteins on the virus’s surface, which are known to cause the reoccurrences of outbreaks internationally. Thus, seven months post the first launch of COVID-19 vaccines, the evolution of coronavirus seems to have stayed ahead of vaccinations.
iXensor Chairmen Dr. Peter Fitzgerald commented, “The COVID-19 rapid antigen test with an integrated data management solution provides the exact security mechanism demanded to protect homes, schools, businesses and communities from being affected by new outbreaks.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, and cardiovascular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom